Lipid modification cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease : full guideline
The scope for this guideline was limited to the identification and assessment of cardiovascular disease (CVD) risk and to the assessment and modification of lipids in people at risk of CVD or people with known cardiovascular disease. The guideline development group wishes to make it clear that lipid...
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
London
National Collaborating Centre for Primary Care
2010, [2010]
|
| Series: | NICE clinical guidelines
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The scope for this guideline was limited to the identification and assessment of cardiovascular disease (CVD) risk and to the assessment and modification of lipids in people at risk of CVD or people with known cardiovascular disease. The guideline development group wishes to make it clear that lipid modification should take place as part of a programme of risk reduction and also include attention to the management of all other known risk factors |
|---|---|
| Item Description: | "May 2008 ; Revised March 2010 following decision by NICE Guidance Executive to modify the recommendations regarding choice of equation for assessment of cardiovascular risk." |
| Physical Description: | PDF file (239 p.) ill |